We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
-16.07%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.14B
AUM Growth
-$212M
(-16%)
Cap. Flow
+$98.4M
Cap. Flow
% of AUM
8.63%
Top 10 Holdings %
Top 10 Hldgs %
46.56%
Holding
206
New
51
Increased
51
Reduced
18
Closed
36
Avg Time Held Equity + Options
3
quarters
Top 10 Avg Time Held Equity + Options
4.1
quarters
Top 20 Avg Time Held Equity + Options
4.2
quarters
Avg Time Held Equity only
3.1
quarters
Top 10 Avg Time Held Equity only
4.1
quarters
Top 20 Avg Time Held Equity only
4.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sarepta Therapeutics
SRPT
|
+$27.8M |
| 2 |
Humana
HUM
|
+$19.1M |
| 3 |
XLRN
Acceleron Pharma
XLRN
|
+$15.3M |
| 4 |
QTNT
Quotient Limited Ordinary Shares
QTNT
|
+$13.2M |
| 5 |
MDVN
MEDIVATION, INC.
MDVN
|
+$12.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DYAX
DYAX CORPORATION
DYAX
|
+$68.4M |
| 2 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$12.9M |
| 3 |
Baxter International
BAX
|
+$10.1M |
| 4 |
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
|
+$8.54M |
| 5 |
NEVRO CORP.
NVRO
|
+$8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.87% |
| 2 | Miscellaneous | 6.35% |
| 3 | Consumer Staples | 0.6% |
| 4 | Consumer Discretionary | 0.11% |
| 5 | Industrials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
DELISTED
Amicus Therapeutics
FOLD
| $129M | 11.29% |
15,239,444
| – | – |
2014 Q1
8 quarters
|
|
2
Neurocrine Biosciences
NBIX
$14.4B
| $108M | 9.44% |
2,720,967
+224,800
| +9% | +$8.92M |
2013 Q2
11 quarters
|
|
|
3
Sarepta Therapeutics
SRPT
$1.84B
| $74.8M | 6.56% |
3,833,128
+1,592,200
| +71% | +$27.8M |
2013 Q2
11 quarters
|
|
|
TSRO
4
DELISTED
TESARO, Inc.
TSRO
| $48.4M | 4.24% |
1,098,659
+130,000
| +13% | +$5.22M |
2013 Q2
11 quarters
|
|
|
AGN
5
DELISTED
Allergan plc
AGN
| $41.5M | 3.64% |
155,000
+10,000
| +7% | +$2.86M |
2015 Q4
1 quarter
|
|
6
Travere Therapeutics
TVTX
$4.9B
| $41M | 3.59% |
2,999,380
+420,000
| +16% | +$6.37M |
2014 Q1
8 quarters
|
|
7
Xencor
XNCR
$1.86B
| $24.2M | 2.12% |
1,804,784
-50,000
| -3% | -$592K |
2013 Q4
9 quarters
|
|
|
ARAV
8
DELISTED
Aravive, Inc. Common Stock
ARAV
| $22.7M | 1.99% |
472,626
+89,384
| +23% | +$4.74M |
2014 Q1
8 quarters
|
|
|
XLRN
9
DELISTED
Acceleron Pharma
XLRN
| $21.2M | 1.86% |
803,036
+527,000
| +191% | +$15.3M |
2014 Q2
7 quarters
|
|
|
GBT
10
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $20.6M | 1.8% |
1,297,468
+110,838
| +9% | +$1.97M |
2015 Q3
2 quarters
|
|
|
11
Humana
HUM
$52.1B
| $20.1M | 1.77% |
+110,000
| New | +$19.1M |
2016 Q1
0 quarters
|
|
|
12
DELISTED
NEVRO CORP.
NVRO
| $19.6M | 1.72% |
348,600
-135,679
| -28% | -$8M |
2014 Q4
5 quarters
|
|
|
QTNT
13
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $19.1M | 1.68% |
54,727
+32,388
| +145% | +$13.2M |
2014 Q2
7 quarters
|
|
14
Talphera
TLPH
$56.1M
| $18.5M | 1.62% |
299,788
| – | – |
2013 Q2
11 quarters
|
|
|
FPRX
15
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $18.5M | 1.62% |
454,129
+20,000
| +5% | +$687K |
2013 Q4
9 quarters
|
|
16
uniQure
QURE
$1.51B
| $17.1M | 1.5% |
1,442,093
+475,000
| +49% | +$7.01M |
2014 Q4
5 quarters
|
|
|
MDVN
17
DELISTED
MEDIVATION, INC.
MDVN
| $15.6M | 1.37% |
+340,000
| New | +$12.3M |
2016 Q1
0 quarters
|
|
|
LJPC
18
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $14.6M | 1.28% |
699,515
+50,000
| +8% | +$892K |
2014 Q3
6 quarters
|
|
19
Iovance Biotherapeutics
IOVA
$6.6B
| $14.2M | 1.24% |
2,787,256
-212,905
| -7% | -$1.17M |
2015 Q1
4 quarters
|
|
|
20
Teva Pharmaceutical Industries Limited
TEVA
$48B
| $14M | 1.23% |
261,000
-220,000
| -46% | -$12.9M |
2015 Q3
2 quarters
|
|
21
DBV Technologies S.A. American Depositary Shares
DBVT
$600M
| $13.6M | 1.19% |
41,670
+10,998
| +36% | +$3.09M |
2015 Q2
3 quarters
|
|
22
Vertex Pharmaceuticals
VRTX
$129B
| $12.7M | 1.12% |
160,000
+50,000
| +45% | +$4.52M |
2015 Q4
1 quarter
|
|
|
CPXX
23
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
| $12.1M | 1.06% |
+1,100,000
| New | +$3.61M |
2016 Q1
0 quarters
|
|
|
24
CALL
Sarepta Therapeutics
SRPT
$1.84B
| $10.7M | 0.94% |
550,000
+50,000
| +10% | +$874K |
2014 Q3
6 quarters
|
|
25
DELISTED
Dermira, Inc.
DERM
| $10.6M | 0.93% |
512,000
+10,000
| +2% | +$245K |
2014 Q4
5 quarters
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q1 2016 Portfolio in Review
As of Q1 2016, Perceptive Advisors held 206 positions worth $1.14B, down 16% from $1.35B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Perceptive Advisors deployed $98.4M of net new capital in Q1 2016, opening 51 new positions and adding to 51 existing holdings. Its largest new stake was Humana: 110,000 shares worth $20.1M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Miscellaneous and Consumer Staples.
On the sell side, the largest reduction was Teva Pharmaceutical Industries Limited, an estimated $12.9M trimmed.
- Perceptive Advisors's largest Q1 2016 buy was Humana: 110,000 shares worth $20.1M.
- Perceptive Advisors added most to Sarepta Therapeutics in Q1 2016, an estimated $27.8M increase.
- Perceptive Advisors's biggest Q1 2016 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $12.9M.
- Perceptive Advisors fully exited DYAX CORPORATION in Q1 2016, selling an estimated $68.4M.
- Perceptive Advisors's ten largest holdings make up 47% of its $1.14B portfolio in Q1 2016.
- Perceptive Advisors opened 51 new positions and closed 36 in Q1 2016.
- Perceptive Advisors's portfolio value fell 16% quarter-over-quarter to $1.14B.
Based on Perceptive Advisors's 13F filing for Q1 2016, filed 16 May 2016.